PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Recs

0
Player Avatar SnowBawl (< 20) Submitted: 3/23/2011 8:36:30 AM : Outperform Start Price: $5.00 PDLI Score: +18.41

Yahoo small cap growth

Report this Post Reply

Featured Broker Partners


Advertisement